Transgene (TRNG)

Currency in EUR
0.679
-0.001(-0.15%)
Real-time Data·
TRNG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6790.681
52 wk Range
0.6701.500
Key Statistics
Prev. Close
0.68
Open
0.681
Day's Range
0.679-0.681
52 wk Range
0.67-1.5
Volume
3.47K
Average Volume (3m)
104K
1-Year Change
-49.5167%
Book Value / Share
0.40
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TRNG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.100
Upside
+62.00%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Transgene News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.100
(+62.00% Upside)

Earnings

Latest Release
Sep 24, 2026
EPS / Forecast
-0.06 / --
Revenue / Forecast
2.99M / --
EPS Revisions
Last 90 days

TRNG Income Statement

Compare TRNG to Peers and Sector

Metrics to compare
TRNG
Peers
Sector
Relationship
P/E Ratio
−5.5x−3.0x−0.3x
PEG Ratio
−0.12−0.030.00
Price/Book
1.7x0.4x2.6x
Price / LTM Sales
33.0x7.6x2.9x
Upside (Analyst Target)
62.2%301.9%64.3%
Fair Value Upside
Unlock0.0%9.2%Unlock

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Employees
152
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
657.64K0.24%445.88K
Other Institutional Investors
9.73M3.55%6.59M
Public Companies & Retail Investors
263.50M96.21%178.65M
Total
273.88M100.00%185.69M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Groupe Industriel Marcel Dassault3.55%9,726,8166,595
Ofi Invest Asset Management0.15%413,539280

People Also Watch

0.7110
ALHAF
+1.43%
0.0353
ALBPS
+11.01%
29.20
EQSE
+0.34%
8.4360
ALSEN
-6.53%
25.64
MEDCL
-2.21%

FAQ

What Is the Transgene (TRNG) Stock Price Today?

The Transgene stock price today is 0.679 EUR.

What Stock Exchange Does Transgene Trade On?

Transgene is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Transgene?

The stock symbol for Transgene is "TRNG."

What Is the Transgene Market Cap?

As of today, Transgene market cap is 185.970M EUR.

What Is Transgene's Earnings Per Share (TTM)?

The Transgene EPS (TTM) is -0.16.

When Is the Next Transgene Earnings Date?

Transgene will release its next earnings report on Nov 09, 2026.

From a Technical Analysis Perspective, Is TRNG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Transgene Stock Split?

Transgene has split 4 times.

How Many Employees Does Transgene Have?

Transgene has 152 employees.

What is the current trading status of Transgene (TRNG)?

As of Oct 23, 2026, Transgene (TRNG) is trading at a price of 0.679 EUR, with a previous close of 0.680 EUR. The stock has fluctuated within a day range of 0.679 EUR to 0.681 EUR, while its 52-week range spans from 0.670 EUR to 1.500 EUR.

What Is Transgene (TRNG) Price Target According to Analysts?

The average 12-month price target for Transgene is 1.100 EUR, with a high estimate of 1.1 EUR and a low estimate of 1.1 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +62.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.